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Objective: The prognostic value of microalbuminuria is unsettled in resistant hypertension. The objective
was to evaluate the importance of baseline and serial changes in albuminuria as predictors of cardiovas-
cular morbidity and mortality in patients with resistant hypertension.
Methods: 531 resistant hypertensives had urinary albumin excretion rate (UAER)measured prospectively
at baseline and at the 2nd year of follow-up. Primary endpoints were a composite of fatal and non-fatal
cardiovascular events, all-cause and cardiovascular mortalities. Total strokes and coronary heart disease
(CHD)eventswere secondaryendpoints.MultipleCox regressionassessed theassociationsbetweenUAER
and endpoints.
Results: After a median follow-up of 4.9 years, 72 patients died, 42 from cardiovascular causes; 96 car-
diovascular events occurred, 42 strokes and 47 CHD events. After adjustment for several cardiovascular
risk factors, baseline UAER, either analyzed as a continuous variable or dichotomized at different cut-off
values, was an independent predictor of the composite endpoint, all-cause and cardiovascular mortality,
strokes and CHD events. Each 10-fold increase in UAER implied a signiﬁcant 1.6, 1.5, 2.0, 1.5 and 1.6-
fold higher risk, respectively, for each of the above endpoints. Serial changes in microalbuminuria status
during follow-up tended to parallel changes in cardiovascular risk, regression of microalbuminuria was
associated with a 27% lower risk and development with a 65% higher risk of having a cardiovascular
event.
Conclusions: Baseline albuminuria strongly predicts cardiovascular morbidity and mortality in resis-
tant hypertensive patients and serial changes in microalbuminuria may translate into changes in risk.
Microalbuminuria reduction may be a goal of anti-hypertensive treatment.
© 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license.. Introduction
Small increases in urinary albumin excretion rate (UAER),
o-called microalbuminuria (MA), have been consistently demon-
trated to predict worse cardiovascular outcomes in diabetic
atients [1,2], and in population-based cohorts [3–5], including
lderly [6] and high cardiovascular risk individuals [7]. However,
he prognostic importance ofMA in hypertensive patients has been
ess extensively evaluated [8–10]. Recently, the classic partition
alue of microalbuminuria (≥30mg/24h or ≥20g/min) has been
uestioned [11] because some studies [12,13] have demonstrated
hat its associated cardiovascular risk seemed to initiate at much
ower UAER values. Furthermore, the prognostic implications of
∗ Corresponding author at: Rua Croton 72, Rio de Janeiro – RJ, CEP: 22750-240,
razil. Tel.: +55 21 2447 3577; fax: +55 21 2562 2514.
E-mail address: gilsalles@hucff.ufrj.br (G.F. Salles).
021-9150 © 2011 Elsevier Ireland Ltd. 
oi:10.1016/j.atherosclerosis.2011.01.026
Open access under the Elsevier OA license.serial changes in UAER during treatment have been addressed in
only one previous report [14].
Resistant hypertension (RH), deﬁned [15] as the failure to con-
trol ofﬁce blood pressure (BP) despite an optimal treatment with
at least 3 anti-hypertensive drugs in full dosages, ideally including
a diuretic, is a common, but generally understudied, clinical condi-
tion with a prevalence of up to 30% of general hypertensives [15].
Because of the persistently elevated BP levels, RH frequently lead
to the rapid development of target-organ damages, and to a high
cardiovascular morbidity and mortality [16–18]. However, as far as
we know, the prognostic importance of MA in patients with RH has
never beenevaluated. Therefore, this prospective studywith a large
cohort of RHpatients followedup for up to 9 years has the following
aims: (1) to examine the prognostic signiﬁcance of baseline UAER
for cardiovascular morbidity and mortality and for all-cause mor-
tality; (2) to verify whether its prognostic value, if it exists, is also
detected at values of UAER below the classic deﬁnition ofMA; (3) to
evaluate whether serial changes in UAER during treatment would
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incidence: 3.92 per 100 patient-years): 38 strokes, 23 AMIs, 1500 G.F. Salles et al. / Athero
ranslate into beneﬁt or harm regarding cardiovascular morbidity
nd mortality.
. Methods
.1. Patients and baseline procedures
The current prospective study included 531 patients with RH
nrolled consecutively between January 1999 and December 2004
n the hypertension outpatient clinic of our university hospital.
tudy protocols were approved by the local Ethics Committee
nd informed consent was obtained from all of the partici-
ants. The enrollment criteria, baseline protocol and diagnostic
eﬁnitions have been detailed previously [17–20]. In brief, all
atients referred to our clinic that fulﬁlled the criteria for RH
ofﬁce BP≥140/90mmHg, using ≥3 anti-hypertensive drugs in
ull dosages, always including a diuretic, and considered at least
oderately adherent by a validated questionnaire) were sub-
itted to a standard protocol that included a thorough clinical
xamination, a laboratory evaluation, and 24-h ambulatory BP
onitoring (ABPM). UAER was measured by immunonephelom-
try (Dade Behring Marburg GmbH, Germany, lowest detection
imit 0.2mg/dL, intra-assay and interassay variation coefﬁcients 4.3
nd 4.4%, respectively) in a sterile 24-h urine collection. ABPM was
ecorded using Mobil O Graph (version 12) equipment (Dynamapa,
ardios, São Paulo, Brazil). A reading was taken every 15min
hroughout the day and every 30min at night. Parameters evalu-
ted were mean 24-h, daytime and nighttime systolic and diastolic
P.
.2. Follow-up and endpoints
Patients were followed up regularly until December 2007.
hirty-ﬁve subjects (6.3%) were lost to follow-up and were consid-
red censored observations at the date of their last hospital visit.
AER measurement was repeated at the end of the 2nd year of
ollow-up in 439 patients (83%). The primary endpoints were a
omposite of all fatal or non-fatal cardiovascular events, all-cause
nd cardiovascular mortalities. Deﬁnitions of endpoints have been
ecently detailed [18,19]. In brief, cardiovascular events were the
ollowing: fatal and non-fatal acute myocardial infarctions (AMIs),
udden cardiac deaths, new-onset heart failure, death from pro-
ressive heart failure, any myocardial revascularization procedure,
atal and non-fatal strokes, any aortic or lower limb revascular-
zation procedure, amputation above the ankle, and deaths from
ortic or peripheral arterial disease. Total coronary heart disease
CHD) events (fatal or non-fatal AMIs, sudden deaths and myocar-
ial revascularizations) and total fatal or non-fatal strokes were
econdary endpoints. Endpoints were ascertained from medical
ecords, death certiﬁcates and interviews with attending physi-
ians and patient families, by a standard questionnaire reviewed
y an independent observer.
.3. Statistical analysis
Continuous data were expressed as means and SD if normally
istributed or asmedians and interquartile range (IQR) if asymmet-
ically distributed. Baseline characteristics between patients with
ndwithoutMAwerecomparedbyunpaired t-test,Mann–Whitney
est or 2 test, when adequate. The assessment of baseline UAER
s an independent predictor of the endpoints was performed by
aplan–Meier estimation of survival curves, compared by log-rank
est, and by multiple Cox proportional hazards analysis. Baseline
AER was examined in the following manners: (1) as a continuous
ariable, log10 transformed due to its positive skewed distribu-
ion; (2) divided into tertiles (<12.5mg/24h, 12.5–27.5mg/24h,sis 216 (2011) 199–204
>27.5mg/24h), with the lowest tertile group as the reference; (3)
dichotomized at the median value (18mg/24h), with the below-
the-median group as the reference; (4) dichotomized at the classic
partition value of MA (30mg/24h). Cox models were ﬁrst adjusted
for age and gender and then, for the composite endpoint and for all-
cause mortality, further adjusted for all potential risk factors: age,
gender, diabetes, current smoking, dyslipidemia, previous cardio-
vascular diseases, serum creatinine (log10 transformed), number
of anti-hypertensive drugs in use, 24-h ambulatory SBP and non-
dipping pattern on ABPM. Because of the smaller number of events
and to avoid overﬁtting, the multivariate Cox analyses for cardio-
vascular mortality and for the secondary endpoints were adjusted
only for their signiﬁcant predictors, beyond age and gender. Inter-
action terms were tested and sensitivity analyses performed for
the composite endpoint regarding age (≥65 years), gender, pres-
ence of diabetes and cardiovascular diseases, serum creatinine
(>115mol/L in men and >106mol/L in women), ambulatory BP
control and dipping status on ABPM.
For the assessment of the prognostic value of serial changes in
UAER, we excluded the individuals who did not provide a valid
24-h urine collection at the end of the 2nd year of follow-up
(92 patients) and those patients who presented a cardiovascu-
lar event during these ﬁrst 2 years of follow-up (26 patients),
because of the possible inﬂuence of this event on UAER; totaling
413 patients in this analysis. Patients were divided into 4 sub-
groups according to the comparison between baseline and 2nd
year UAER: (1) persistent normoalbuminuria; (2) development of
MA; (3) regression of MA; (4) persistent classic MA. Changes from
baseline to 2nd year in blood pressure and renal function mea-
surements were compared by one-way ANOVA or Kruskal–Wallis
test among the 4 subgroups. Kaplan–Meier analysis of survival
curves and multiple Cox regression were carried on for these 4
subgroups. Multiple Cox analyses were adjusted for age, gender,
serum creatinine, ambulatory 24-h SBP, non-dipping pattern and
number of anti-hypertensive drugs in use; these last 4 variables
were also obtained at the end of the 2nd year of follow-up. Statis-
tics were performed with SPSS version 13.0 package (SPSS Inc.,
Chicago, IL), and a 2-tailed probability value <0.05 was considered
signiﬁcant.
An expanded Section 2 is available on-line.
3. Results
3.1. Baseline characteristics and follow-up endpoints
Baseline median UAER was 18.4mg/24h (IQR: 10.0–41.7mg/
24h), and 177 patients (33%) presented classic MA. Table 1 out-
lines the baseline characteristics of patients with and without
MA. Patients with MA were younger, more frequently males,
had a higher prevalence of diabetes, higher serum total choles-
terol, triglycerides and creatinine and lower HDL-cholesterol levels
than normoalbuminuric patients. They also had higher ofﬁce and
ambulatory BPs, and higher prevalences of uncontrolled (true) RH
and non-dipping pattern on ABPM. Anti-hypertensive treatment
was equal between the 2 subgroups, except that microalbumin-
uric patients used more frequently direct vasodilators (mainly
hydralazine) than normoalbuminuric subjects.
During a median follow-up of 4.9 years (2604 patient-years),
96 ﬁrst fatal or non-fatal cardiovascular events occurred (crudemyocardial revascularizations, 9new-onsetheart failures, 7 sudden
deaths, and 4 peripheral or aortic events. There were 72 all-cause
deaths and 42 cardiovascular deaths, 47 total CHD events and 42
strokes. Patients with classic MA had a higher incidence of the 3
primary endpoints than normoalbuminuric patients (Table 1).
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Table 1
Baseline characteristics and crude incidence rates of endpoints during follow-up in patients grouped according to the presence or absence of abnormal urinary albumin
excretion rate (≥30mg/24h).
Characteristics Patients with normoalbuminuria (n=354) Patients with microalbuminuria (n=177) p-Value
Gender, % male 25.7 35.0 0.033
Age, years 67.1 (11.0) 63.1 (11.2) <0.001
BMI, kg/m2 29.7 (5.7) 30.8 (6.1) 0.06
Diabetes, % 29.7 46.9 <0.001
Current smoking, % 8.2 13.0 0.09
Dyslipidemia, % 88.1 89.3 0.77
Previous cardiovascular diseases, % 44.6 46.9 0.64
Total cholesterol, mmol/L 5.66 (1.23) 5.96 (1.44) 0.014
HDL-cholesterol, mmol/L 1.26 (0.33) 1.16 (0.31) 0.001
Triglycerides, mmol/L 1.47 (1.02–2.04) 1.70 (1.20–2.40) 0.001
Serum creatinine, mol/L 80 (71–97) 97 (71–124) <0.001
Creatinine clearance, ml/min/1.73m2 69 (53–93) 65 (46–92) 0.18
Anti-hypertensive treatment
Number of anti-hypertensive drugs in use 4 (3–5) 4 (3–5) 0.06
ACE inhibitors/AR blockers, % 87.5 91.0 0.23
Beta blockers, % 77.4 80.1 0.50
Calcium channel blockers, % 49.7 50.6 0.93
Direct vasodilators, % 30.8 42.0 0.012
Central  agonists, % 14.4 17.0 0.44
Ofﬁce SBP, mmHg 176 (27) 182 (28) 0.033
Ofﬁce DBP, mmHg 98 (18) 103 (18) 0.001
24-h SBP, mmHg 133 (18) 146 (19) <0.001
24-h DBP, mmHg 77 (12) 85 (13) <0.001
Non-dipping pattern, % 61.3 70.7 0.042
Uncontrolled ambulatory BP, % 51.1 80.7 <0.001
Number of all-cause deaths (incidence rate, per
100 patient-years of follow-up)
35 (1.98) 37 (4.44) 0.001
Number of cardiovascular deaths (incidence
rate, per 100 patient-years of follow-up)
18 (1.02) 24 (2.88) 0.001
Number of total cardiovascular events
(incidence rate, per 100 patient-years of
follow-up)
48 (2.84) 48 (6.29) <0.001
Values are means (standard deviations) or proportions, except for triglycerides, serum creatinine, creatinine clearance and number of anti-hypertensive drugs that are
medians (interquartile ranges) and endpoints occurrence that is absolute number (incidence rate).
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.2. Prognostic value of baseline UAER
Table 2 presents the results of Cox analyses of baseline UAER for
rediction of primary endpoints. Analyzed as a continuous variable,
ach 10-fold increase in UAER was associated with a signiﬁcant
0% increased risk of having a cardiovascular event and all-cause
eath, andwithanearly2-fold increased riskofdying fromacardio-
ascular cause. When divided into tertiles, patients in the middle
ertile (UAER between 12.5 and 27.5mg/24h) had a borderline
0% increased risk of presenting a cardiovascular event, whereas
atients in the upper tertile subgroup had signiﬁcantly increased
isks of cardiovascular morbidity and mortality and of all-cause
ortality in relation to the lower tertile subgroup. Regardless of
ichotomizing at the median value or at the classic partition value
fMA, patientswith higher UAERhad a signiﬁcantlyworse progno-
is, except for all-causemortalitywhendichotomizedat themedian
alue. Kaplan–Meier analysis of cumulative-event curves (Fig. 1
nd S1, the last one available as supplementary on-line material)
orroborated the worse prognosis of patients with higher UAER.
able S1, Supplementarydata, available as supplementarymaterial,
resents the results regarding secondary endpoints. Baseline UAER
qually predicted coronary and cerebrovascular events, although
he prediction of CHD events seemed to initiate at lower UAER
alues than the prediction of strokes: patients in the middle ter-
ile subgroup had a marginally 2.4-fold increased risk of having a
HD event, but no increased risk of stroke; a 2.3-fold increased risk
f stroke only appeared in the upper tertile and in the classic MA
ubgroups. The inclusion of the use of statins as a covariate in the
ultivariate analysis did not change any of the results at all.onverting enzyme; AR, angiotensin II receptor; SBP, systolic blood pressure; DBP,
Regarding sensitivity analysis, a signiﬁcant interaction (p=0.05)
was found between MA and presence of prior cardiovascu-
lar diseases at baseline. The association between cardiovascular
prognosis and MA was stronger in patients without previous car-
diovascular diseases (HR: 3.41, 95%CI: 1.66–6.99) than in those
with established cardiovascular diseases at entry (HR: 1.31, 95%CI:
0.71–2.42). No other interaction was observed (all p>0.20). In
particular, the prognostic value of MA was equal in diabetic
(HR: 2.43, 95%CI: 1.19–4.96) and in non-diabetic patients (HR:
1.83, 95%CI: 1.00–3.37). Also, no change in the prognostic impor-
tance of baseline UAER was observed after exclusion of 31
patients (6%) with macroalbuminuria (UAER>300mg/24h or pro-
teinuria >0.5 g/24h), signifying that the prognostic impact of UAER
was not exclusively driven by those with the highest UAER values.
3.3. Prognostic value of serial changes in UAER during follow-up
There was an overall median 3mg/24h (IQR: −6 to 12mg/24h)
decrease between baseline and 2nd year UAER. Among the 413
patients who had a valid 2nd year UAER measurement and no
event during the ﬁrst 2 years of follow-up, 243 (59%) patients per-
sisted without classic MA, 97 (24%) persisted with MA, 39 patients
regressed MA (29% of those with baseline MA) and 37 patients
developed MA (12% of normoalbuminuric individuals at baseline).
TableS2, Supplementarydata, availableasSupplementarymaterial,
presents baseline and 2nd year blood pressure and renal func-
tion measurements in these subgroups. Patients who regressed
or prevented MA had non-signiﬁcant higher decreases in blood
pressures whereas those who persisted with MA had a signiﬁcant
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Table 2
Results of Cox survival analyses for associations between urinary albumin excretion rate and primary endpoints.
UAER parameters Composite endpoint (n=96) All-cause mortality (n=72) Cardiovascular mortality (n=42)
Age and gender adjusted Multivariate adjusteda Age and gender adjusted Multivariate adjusteda Age and gender adjusted Multivariate adjustedb
Continuous UAER (1 log10) 1.89 (1.45–2.46)* 1.56 (1.15–2.11)† 1.98 (1.44–2.73)* 1.53 (1.07–2.21)‡ 2.14 (1.43–3.20)* 1.97 (1.31–2.96)*
Tertiles of UAER
1st tertile (<12.5mg/24h) Reference Reference Reference Reference Reference Reference
2nd tertile (12.5–27.5mg/24h) 1.83 (1.00–3.34)‡ 1.79 (0.98–3.29) 1.27 (0.65–2.51) 1.33 (0.67–2.64) 1.35 (0.52–3.49) 1.53 (0.59–3.97)
3rd tertile (>27.5mg/24h) 3.52 (1.97–6.27)* 2.65 (1.44–4.89)† 3.06 (1.62–5.76)* 2.16 (1.09–4.25)‡ 4.04 (1.71–9.54)* 3.54 (1.49–8.45)†
Classic microalbuminuria (UAER≥30mg/24h) 2.63 (1.74–3.97)* 1.95 (1.25–3.06)† 2.84 (1.75–4.60)* 1.92 (1.13–3.27)‡ 3.61 (1.92–6.78)* 2.93 (1.54–5.54)*
UAER above the median (>18mg/24h) 2.04 (1.32–3.16)* 1.73 (1.10–2.72)‡ 1.72 (1.05–2.83)‡ 1.34 (0.80–2.67) 2.69 (1.34–5.41)† 2.54 (1.25–5.16)†
Values are hazard ratios (95% conﬁdence intervals).
Abbreviation: UAER, urinary album in excretion rate.
a Adjusted for gender, age, diabetes, current smoking, dyslipidemia, previous cardiovascular diseases, serum creatinine (log10 transformed), number of anti-hypertensive drugs in use, ambulatory 24-h systolic blood pressure
and non-dipping pattern.
b Adjusted for age, gender, current smoking, number of anti-hypertensive drugs in use, and non-dipping pattern on ambulatory BP monitoring.
* p<0.001.
† <0.01.
‡ <0.05.
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Table 3
Results of Cox survival analyses for associationsbetweenchanges inurinary albumin
excretion rate during the ﬁrst two years of follow-up and incidence of fatal or non-
fatal cardiovascular events after the second year of follow-up.
Serial changes in UAER Composite endpoint (n=70)
Age and gender adjusted Multivariate adjusteda
Persisted without
microalbuminuria
(n=243, 31 events)b
0.41 (0.24–0.70)* 0.51 (0.29–0.92)‡
Regressed
microalbuminuria
(n=39, 7 events)b
0.59 (0.26–1.37) 0.73 (0.31–1.72)
Developed
microalbuminuria
(n=34, 7 events)c
1.63 (0.72–3.70) 1.65 (0.72–3.78)
Persisted with
microalbuminuria
(n=97, 25 events)c
2.45 (1.42–4.23)* 1.95 (1.09–3.48)‡
Values are hazard ratios (95% conﬁdence intervals).
Abbreviation: UAER, urinary album in excretion rate.
a Adjusted for age, gender, and for serum creatinine (log10 transformed), ambu-
latory 24-h SBP, dipping pattern and number of anti-hypertensive drugs in use
(obtained at the 2nd year of follow-up).
b Hazard ratios estimated in relation to the group persistently with microalbu-
minuria.
c
b
n
i
u
h
n
c
t
o
F
p
oHazard ratios estimated in relation to the group persistently without microal-
uminuria.
* p<0.001.
‡ p<0.05.
on-signiﬁcant 27% lower risk of cardiovascular morbi-mortality
n comparison to those with persistent MA, whereas those individ-
als who developed MA had a non-signiﬁcant 65% increased risk of
aving a cardiovascular event in relation to those with persistent
ormoalbuminuria. Kaplan–Meier analysis of incident cardiovas-
ular event curves (Fig. 2) conﬁrmed the trend of the curve of
he subgroup that regressed MA to become closer to the curve
f the persistently normoalbuminuric group, while the curve of
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ig. 2. Kaplan–Meier estimation curve of cumulative total cardiovascular events in
atients divided into 4 subgroups according to prevention, regression, development
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the subgroup that developed MA approximated the persistently
microalbuminuric group curve.
4. Discussion
This prospective cohort study has three key ﬁndings. First, base-
line UAER is a powerful risk predictor for cardiovascular morbidity
and mortality and for all-cause mortality in patients with RH. Its
prognostic value is independent of traditional cardiovascular risk
factors, renal function and ambulatory BP levels, and is stronger in
patients without prior cardiovascular diseases. Second, the prog-
nostic impact of UAER for cardiovascular morbidity and mortality
appears to begin at values between 12.5 and 18mg/24h, much
lower than the partition value of classic MA deﬁnition, except
speciﬁcally for stroke predictionwhere it seems to initiate at values
near the classic MA cut-off value. Third, serial changes in MA status
during treatment may be translated into changes in cardiovascular
risk, although the small number of patients and events in the sub-
groups that changed MA status precluded a more comprehensive
analysis.
To the best of our knowledge, this is the ﬁrst prospective study
on the prognostic signiﬁcance of UAER in RH patients, an impor-
tant but generally understudied subgroupof general hypertensives.
It extends the accepted prognostic power of MA for cardiovascu-
lar risk stratiﬁcation to patients with RH. Of note, we found HRs
for baseline UAER very similar to previous studies in hypertensives
and in population-based samples, generally ranging from 1.5 to 3.0
for several cardiovascular outcomes [21], regardless of themethods
(most of previous studies used urinary albumin-to-creatinine ratio
[UACR] in a single morning spot) and of the partition value of MA
used. For example, the losartan intervention for endpoint reduction
in hypertension (LIFE) study [10], which enrolled hypertensives
with electrocardiographic left ventricular hypertrophy, reported
HRs for 10-fold increase inUACRof 1.55, 1.66 and1.85, respectively,
for the composite endpoint, all-cause mortality and cardiovascu-
lar mortality, ﬁgures very similar to ours for 10-fold increments
in UAER. Also, the observation that the prognostic impact of base-
line UAER initiate at values well below the classic MA partition
value is supported by several previous reports, both in hyperten-
sives [9,10,22] and in population-based studies [5,7,12,13]. Hence,
individuals with albuminuria below the classic deﬁnition of MA
should not be considered “normoalbuminurics” in terms of cardio-
vascular risk stratiﬁcation, unless at very low UAER levels (below
12mg/24h) [23].
The prognostic signiﬁcance of changes in albuminuria during
treatment has been addressed in only one previous report from the
LIFE trial [14]. The investigators demonstrated that reduction from
above to below themedian value of UACR between baseline and 1st
year of follow-up was associated with a decrease in crude cardio-
vascular event incidence from 13.5 to 9.4% in comparison to those
patients who persisted with UACR above the median on the two
occasions, whereas an increase from below to above the median
UACR value was associated with an increase in cardiovascular inci-
dence rate from 5.5% to 8.6% in relation to those individuals with
persistently low UACR. However, the authors did not provide esti-
mates of hazard increase or decrease associated with changing MA
status. Our analysis supported these ﬁndings by showing a trend
towards a 27% lower cardiovascular risk in patients who regressed
MA and a 65% greater risk in those who developed MA between
baseline and 2nd year of follow-up, and that these changes in risk
were independent of changes in ambulatory BP and renal function
during follow-up. If the observation that changes in albuminuria
translates into parallel changes in cardiovascular risk is further
conﬁrmed in other prospective studies in general hypertensives,
then measurement of albuminuria at baseline and serially during
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reatment should become an integrated part of arterial hyperten-
ion management to monitor risk [23], similar to what is presently
ecommended for type 2 diabetic patients [24].
The physiopathological mechanisms linking increases in UAER
o cardiovascular morbidity and mortality are largely unsettled.
he most accepted interpretation is the STENO hypothesis [25],
n which increased urinary albumin leakage probably reﬂects
idespread vascular damage, including endothelial dysfunction
nd low-grade chronic systemic inﬂammation, which precede
therosclerotic vascular diseases. In this sense, albuminuria may
epresent an integrated marker of structural and functional abnor-
alities in hypertensive patients, including pre-clinical conditions
uch as hypertensive vascular alterations [26] (central arterial stiff-
ess and microvascular dysfunction), left ventricular hypertrophy
27] and renal function impairment [26].
This study has some limitations that warrant discussion. First,
s pointed out before, the analyses regarding cardiovascular
ortality, secondary endpoints and, specially, serial changes in
lbuminuria should be faced with caution because of the smaller
umber of events that prevented more comprehensive statistical
djustments. Second, UAER was measured on a single 24-h urine
ollection at baseline and at the 2nd year of follow-up, which is
urely more reproducible than measuring UACR on a single urine
pot as most of the previous studies did, but did not take into
ccount the daily physiological variability of UAER. However, the
egressiondilution bias introducedby a singlemeasurementwould
end to underestimate the strength of the association between
AER and cardiovascular outcomes. This suggests that the true
ssociationmaybeeven stronger thanobserved. Third, as this study
ncluded only resistant hypertensive patients, our ﬁndingsmay not
e generalized to other less severe hypertensive individuals.
In conclusion, this study provides evidence that baseline albu-
inuria is a powerful cardiovascular risk marker in patients with
esistant hypertension and risk begins at UAER values well below
he classic microalbuminuria partition value. Furthermore, serial
hanges in microalbuminuria status during treatment may tend to
arallel changes in cardiovascular risk. Other prospective studies in
eneral hypertensives are needed to conﬁrm the prognostic impor-
ance of changes in albuminuria during treatment. If it is conﬁrmed,
eduction in urinary albumin excretion may become a therapeutic
oal in arterial hypertension management.
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